InspireMD (NSPR) AI Stock Analysis

• Market Cap: $68.01M
• Dividend Yield: N/A
• Average Volume (3M): 251.31K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: 8.49%
• EPS Growth: 6.09%
• Country: US
• Employees: 85
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.22
• Shares Outstanding: 30,635,345
• 10 Day Avg. Volume: 668,558
• 30 Day Avg. Volume: 251,307
• PEG Ratio: -0.02
• Price to Book (P/B): 0.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.42
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -0.09
• Enterprise Value/Gross Profit: -1.73
• Enterprise Value/Ebitda: 0.02
• 1Y Price Target: $3.83
• Price Target Upside: 57.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 50 Neutral
• Price Target: $2.50 ▲(2.88%Upside)

InspireMD's financial performance is constrained by profitability and cash flow issues, impacting its attractiveness. However, recent regulatory approvals and strategic corporate moves offer future growth prospects. Technical indicators point to a neutral to bearish trend.

Positive Factors

Acquisition Potential

InspireMD could be an attractive add-on for Boston or other big MedTech cardiovascular players.

Analyst Recommendation

Analyst recommends a Buy rating and a $5 price target.

Business Growth

InspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.

Market Share

Best-in-class data should result in fast share taking for InspireMD's CGuard.

Product Performance

The 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%, supporting a quick share shift within the TF-CAS market.

Regulatory Approval

InspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.

Negative Factors

InspireMD Business Overview & Revenue Model

Company Description

InspireMD, Inc. (NSPR) is a medical device company focused on the development and commercialization of its proprietary MicroNet™ technology for the treatment of complex vascular and coronary artery diseases. The company's flagship product is the CGuard™ Embolic Prevention System (EPS), which is designed to prevent embolization in carotid artery stenting procedures. InspireMD operates primarily in the cardiovascular sector, offering innovative solutions aimed at improving patient outcomes in the treatment of vascular diseases.

How the Company Makes Money

InspireMD generates revenue through the sale of its CGuard™ Embolic Prevention System and other related products that utilize its MicroNet™ technology. The company's primary revenue stream comes from the direct sales of these medical devices to hospitals, clinics, and other healthcare providers. InspireMD may also earn income through strategic partnerships and distribution agreements with medical device distributors and healthcare organizations. The success of its revenue model is significantly influenced by the clinical adoption of its products, regulatory approvals, and the expansion of its distribution network in various global markets.

InspireMD Financial Statement Overview

Summary

InspireMD demonstrates revenue growth but faces significant profitability and cash flow challenges. The strong equity position is overshadowed by ongoing operational losses and negative cash flows, posing potential risks. Strategic improvements in operational efficiency and cost management are essential.

Income Statement

InspireMD has shown a consistent increase in revenue over the years, with a revenue growth rate of 12.95% from 2023 to 2024. However, the company struggles with profitability as indicated by its negative net profit margin of 22.22% in 2024 and a negative EBIT margin of 47.79%. The consistent negative EBITDA margin suggests ongoing operational challenges.

Balance Sheet

The company's balance sheet reflects a solid equity position with an equity ratio of 77.06% in 2024, indicating financial stability. However, the high debt-to-equity ratio of 0.05 suggests a manageable but present level of leverage. Return on equity is positive at 4.31% for 2024, indicating some profitability despite overall losses.

Cash Flow

InspireMD's cash flow statement reveals challenges in generating positive cash flows, with a significant negative free cash flow in 2024. The operating cash flow to net income ratio is negative, indicating issues in translating income into cash. The free cash flow to net income ratio is also negative, further emphasizing liquidity concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.03M	7.01M	6.21M	5.17M	4.50M	2.48M
Gross Profit	1.51M	1.51M	1.81M	1.12M	754.00K	83.00K
EBITDA	-37.24M	-33.22M	-20.91M	-18.52M	-14.55M	-10.23M
Net Income	-36.14M	-32.01M	-19.92M	-18.49M	-14.92M	-10.54M
Balance Sheet
Total Assets	38.67M	46.81M	47.64M	24.65M	39.71M	17.78M
Cash, Cash Equivalents and Short-Term Investments	26.09M	34.64M	39.02M	17.80M	34.04M	12.64M
Total Debt	1.64M	2.34M	1.59M	1.61M	1.20M	999.00K
Total Liabilities	2.96M	10.72M	8.14M	7.26M	6.18M	5.61M
Stockholders Equity	28.34M	36.09M	39.50M	17.39M	33.53M	12.16M
Cash Flow
Free Cash Flow	-27.16M	-23.27M	-16.76M	-16.02M	-13.55M	-9.17M
Operating Cash Flow	-25.60M	-21.87M	-16.38M	-15.54M	-13.21M	-9.08M
Investing Cash Flow	9.53M	12.64M	-16.09M	8.44M	-22.46M	-187.00K
Financing Cash Flow	18.96M	18.45M	37.53M	-140.00K	35.03M	16.39M

InspireMD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.43
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NSPR, the sentiment is Positive. The current price of 2.43 is above the 20-day moving average (MA) of 2.36, above the 50-day MA of 2.43, and below the 200-day MA of 2.66, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 54.16 is Neutral, neither overbought nor oversold. The STOCH value of 67.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NSPR.

InspireMD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SRTS	66 Neutral	$75.48M	41.95	3.46%	―	24.75%	-61.29%
Sector *	59 Neutral	HK$15.37B	5.76	-7.44%	4.08%	11.55%	-28.15%
HYPR	52 Neutral	$59.55M	―	-67.86%	―	0.34%	6.20%
NSPR	50 Neutral	$68.01M	―	-113.95%	―	8.49%	6.09%
ICCM	47 Neutral	$59.40M	―	-173.47%	―	0.34%	9.38%
CTSO	46 Neutral	$64.49M	―	-94.65%	―	-5.86%	50.76%
VANI	44 Neutral	$75.24M	―	-117.76%	―	―	15.22%

InspireMD Corporate Events

InspireMD Launches CGuard Prime Stent in U.S. Market

On July 9, 2025, InspireMD announced the U.S. commercial launch of its CGuard® Prime Carotid Stent System, following FDA premarket application approval. This launch represents a significant milestone for InspireMD, which has already captured a double-digit market share in over 30 countries. The CGuard Prime is designed to enhance embolic protection and improve patient safety in stroke prevention, featuring a dual-layer design and SmartFit™ technology. The launch is expected to strengthen InspireMD’s position in the U.S. market, supported by a seasoned commercial team and robust operational infrastructure.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Gains FDA Approval for CGuard Stent System

On June 23, 2025, InspireMD announced that the FDA granted premarket approval for its CGuard Prime Carotid Stent System in the United States, marking a significant milestone for the company. The approval, supported by the C-GUARDIANS pivotal trial, positions InspireMD to launch the stent system in the U.S. market, potentially impacting the carotid stenting industry by offering a less invasive treatment option for carotid artery disease.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Gains CE Mark Approval for CGuard® Prime

On June 13, 2025, InspireMD announced it received CE Mark approval under the European Medical Device Regulation (MDR) for its CGuard® Prime Embolic Prevention System (EPS), a significant milestone for the company. This approval allows for the commercial launch of CGuard® Prime EPS in European markets, enhancing InspireMD’s position in carotid stenting innovation and paving the way for a potential U.S. launch pending FDA approval, thereby expanding its market reach and operational scale.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Holds Annual Stockholders Meeting and Elections

On June 3, 2025, InspireMD, Inc. conducted its annual meeting of stockholders, where 66.84% of the shares were represented, constituting a quorum. During the meeting, stockholders re-elected Michael Berman and Scott R. Ward as Class 2 directors for a three-year term and ratified Kesselman & Kesselman as the independent auditors for the 2025 fiscal year.

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

InspireMD Appoints New CFO Amidst Strategic Expansion

On June 3, 2025, InspireMD announced the appointment of Michael Lawless as Chief Financial Officer, effective by June 30, 2025. Lawless, who brings extensive financial leadership experience from the healthcare sector, will replace Craig Shore, who has been with the company for nearly 15 years. This leadership change comes as InspireMD prepares for the U.S. launch of its CGuard Prime system, marking a significant phase in its commercial expansion. In connection with his appointment, Lawless will receive an inducement grant of restricted stock and stock options, which will vest over three years, aligning with Nasdaq Listing Rule 5635(c)(4).

The most recent analyst rating on (NSPR) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.